ReviewClinical microbiology reviews1995
Antiviral therapy for human immunodeficiency virus infections.
Review in Clinical microbiology reviews, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Trial
- Antiviral activities of four marine sulfated glycans against adenovirus and human cytomegalovirus.Antiviral research · 2021Article
- Make it clean, make it safe: A review on virus elimination via adsorption.Chemical engineering journal (Lausanne, Switzerland : 1996) · 2021Article
- Review
- Structure-Activity-Relationship and Mechanistic Insights for Anti-HIV Natural Products.Molecules (Basel, Switzerland) · 2020Review
- In vitro anti-HIV-1 activity of ethyl gallate.Virusdisease · 2020Article
- Effect of 3, hydroxy-lup- 20(29)-en-28-oic acid on 7,12-Dimethylbenz(a) anthracene impaired cellular homeostasis in extrahepatic organs of Sprague Dawley rats.Journal of xenobiotics · 2017Article
- N-Pyrrylarylsulfones with High Therapeutic Potential.Molecules (Basel, Switzerland) · 2017Review
- Modulatory Effect of Betulinic Acid on the Genotoxicity Induced by Different Mutagens in V79 Cells.Evidence-based complementary and alternative medicine : eCAM · 2016Article
- Natural Products as Anti-HIV Agents and Role in HIV-Associated Neurocognitive Disorders (HAND): A Brief Overview.Frontiers in microbiology · 2015Review
- Dendrimers as potential therapeutic tools in HIV inhibition.Molecules (Basel, Switzerland) · 2013Review
- An analog of the natural steroidal alkaloid cortistatin A potently suppresses Tat-dependent HIV transcription.Cell host & microbe · 2012Article
- HiTSEE KNIME: a visualization tool for hit selection and analysis in high-throughput screening experiments for the KNIME platform.BMC bioinformatics · 2012Article
- Hypericum lanceolatum (Hypericaceae) as a potential source of new anti-malarial agents: a bioassay-guided fractionation of the stem bark.Malaria journal · 2011Article
- Suppression of STAT3 and HIF-1 alpha mediates anti-angiogenic activity of betulinic acid in hypoxic PC-3 prostate cancer cells.PloS one · 2011Article
- Data mining using template-based molecular docking on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1RT inhibitors.Journal of molecular modeling · 2008Article
- Molecular docking studies on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1 NNRT inhibitors.Journal of computer-aided molecular design · 2008Article
- Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2.Antimicrobial agents and chemotherapy · 2008Article
- Polycitone A, a novel and potent general inhibitor of retroviral reverse transcriptases and cellular DNA polymerases.The Biochemical journal · 1999Article
- Plant products as antimicrobial agents.Clinical microbiology reviews · 1999Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depending on the stage of their intervention with the viral replicative cycle, human immunodeficiency virus inhibitors could be divided into the following groups: (i) adsorption inhibitors (i.e., CD4 constructs, polysulfates, polysulfonates, polycarboxylates, and polyoxometalates), (ii) fusion inhibitors (i.e., plant lectins, succinylated or aconitylated albumins, and betulinic acid derivatives), (iii) uncoating inhibitors (i.e., bicyclams), (iv) reverse transcription inhibitors acting either competitively with the substrate binding site (i.e., dideoxynucleoside analogs and acyclic nucleoside phosphonates) or allosterically with a nonsubstrate binding site (i.e., non-nucleoside reverse transcriptase inhibitors), (v) integration inhibitors, (vi) DNA replication inhibitors, (vii) transcription inhibitors (i.e., antisense oligodeoxynucleotides and Tat antagonists), (viii) translation inhibitors (i.e., antisense oligodeoxynucleotides and ribozymes), (ix) maturation inhibitors (i.e., protease inhibitors, myristoylation inhibitors, and glycosylation inhibitors), and finally, (x) budding (assembly/release) inhibitors. Current knowledge, including the therapeutic potential, of these various inhibitors is discussed. In view of their potential clinical the utility, the problem of virus-drug resistance and possible strategies to circumvent this problem are also addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.